官方微信|手機版

產(chǎn)品展廳

產(chǎn)品求購企業(yè)資訊會展

發(fā)布詢價單

化工儀器網(wǎng)>產(chǎn)品展廳>試劑標物>行業(yè)專用試劑>生物試劑>89810-- Rapid Equilibrium Dialysis (RED) De...

分享
舉報 評價

89810-- Rapid Equilibrium Dialysis (RED) Device

具體成交價以合同協(xié)議為準
  • 公司名稱 北京華夏遠洋科技有限公司
  • 品牌 Thermofisher Scientific/賽默飛世爾
  • 型號 89810--
  • 產(chǎn)地 Thermo pierce
  • 廠商性質(zhì) 代理商
  • 更新時間 2017/8/16 16:01:05
  • 訪問次數(shù) 3000
產(chǎn)品標簽

pierce

聯(lián)系我們時請說明是化工儀器網(wǎng)上看到的信息,謝謝!


      北京華夏遠洋科技有限公司位于北京市海淀區(qū),臨近北京大學,清華大學,中國農(nóng)業(yè)大學(西區(qū)),中國農(nóng)業(yè)*畜牧研究所和植物保護所,中國醫(yī)學院藥用植物研究所,解放軍309醫(yī)院,中國林業(yè)*,*植物研究所等等各大高校、醫(yī)院和科研單位。是一家專業(yè)從事Qiagen, Roche, Toyobo,Sigma, Amresco, Invitrogen,  Abcam, Santa cruz, Fermantas(MBI), NEB, Omega, Biomiga, BD, Peprotech, Abnova, R&D systerms, GE, Biovision, Millipore, Merck, CST, Axygen, Corning, NUNC, Thermo fihser, Genscript等各大世界生命科學產(chǎn)品的代理,訂購,經(jīng)銷批發(fā)的生物商城。

      華夏遠洋堅持信譽*,踏實誠信為Z高目標的服務(wù)思想。商城產(chǎn)品齊全、*合理。擁有一支嚴格律己、重信用、守信譽的年輕銷售隊伍。不斷更新市場的經(jīng)營銷售對策與方案,與時俱進,時刻堅持薄利多銷的原則,旨在贏得廣大客戶的信賴與發(fā)自內(nèi)心的支持!

Genscript(北京一級代理),USCN(北京一級代理),Qiagen、Toyobo、Sigma、Amresco、Roche、Santa cruz、Fermantas、Abcam、Invitrogen、GE、CST、R&D systems、Omega、Biomiga、Biovision、Merck、Corning、Axygen、NUNC、BD、Thermo、Millipore、碧云天、南京建成、杭州愛思進、LetPub專業(yè)SCI論文編輯北京辦事處、技術(shù)服務(wù)項目。

Rapid Equilibrium Dialysis (RED) Device   

The Thermo Scientific Pierce RED Device for Rapid Equilibrium Dialysis was developed in close association with the pharmaceutical industry to provide the easiest, fastest and most reliable system for performing plasma protein-binding assays, which comprise a critical step in drug development.

The RED Device is an apparatus for performing equilibrium dialysis experiments in a high throughput, automation-compatible format. The device consists of disposable inserts and a base plate formatted to a standard microplate footprint. The RED Device has been extensively validated for plasma-binding assays producing results consistent with those reported in the literature. The Rapid Equilibrium Dialysis (RED) Device offers significant improvements in automation, time requirements, versatility and product reliability compared to other commercially available systems.
Highlights of the Rapid Equilibrium Dialysis Device:
    • Easy and ready to use – disposable tubes require no presoaking, assembly or specialized equipment
    • Designed for speed – the high surface-to-volume ratio of the insert design enables equilibrium to be reached in as few as 100 minutes with vigorous agitation or in three to four hours with 200rpm agitation
    • Automation-compatible – designed on a standard 96-well plate template suitable for automated liquid handlers
    • Flexible and scalable – perform any number of assays (1 to 48 assays per plate) without wasting the entire plate
    • Robust – compartmentalized design eliminates potential for cross talk or leakage
    • Reproducible and accurate – validated for plasma binding assays, producing results consistent with those reported in literature
    • Quality-tested – each lot of inserts is functionally tested in a protein-binding assay for guaranteed performance
Features of the RED Device Inserts:
Each single-use, disposable insert is made of two side-by-side chambers separated by a vertical cylinder of dialysis membrane (in 8K, 12K or 25K MWCO) validated for minimal nonspecific binding. This format requires no extensive assembly steps or specialized equipment, and each chamber or well is easily accessible from the top of the insert after insertion in the base plate. Additionally, the high surface-to-volume ratio of the membrane compartment allows rapid dialysis, where equilibrium can be reached in 4 hours with high levels of reproducibility and accuracy. In many cases, experiments can be completed in less than 100 minutes.
Insert Features:
  • Disposable: require no presoaking, assembly, or specialized equipment
  • Short incubation time: large dialysis surface area accelerates equilibrium
  • 8K MWCO membrane: ideal molecular-weight cutoff for protein-drug binding studies
  • 12K or 25K MWCO membranes are also available as a custom order (minimum order, 10 plates) for larger drug molecules retained by the standard 8K MWCO
  • Membrane composition: regenerated cellulose with low glycerol content as a humectant
Features of the RED Device Base Plates:
RED Device Inserts are designed to be used with either the reusable PTFE or disposable high-density polypropylene base plates. Each RED Device Base Plate holds up to 48 RED Device Inserts and has a standard 96-well plate footprint with 9mm x 9mm well spacing to provide compatibility with automated liquid handling systems. In addition, the disposable RED Device Base Plates are available pre-loaded, providing operation convenience for scientists conducting protein-binding applications. No pre-conditioning of the membrane inserts is needed. When using radioactive materials, this single-use plate is easily disposed of to avoid contamination and cleaning. RED Device Inserts and Base Plates are also available separay.
Base Plate Features:
  • Microplate footprint: compatible with automated systems for 96-well plates
  • Compartmentalized: eliminates potential for crosstalk or leakage
  • PTFE construction: eliminates nonspecific binding and risk of contamination
  • Accepts 1 to 48 inserts: run exactly the number of assays needed without waste
Applications for RED Device:
  • Determination of free vs. drug bound to plasma proteins
  • Pharmacokinetics studies
  • Formulation of drug dosage for in vivo studies
  • Drug-drug interaction studies
  • Selection criteria during drug lead optimization
  • Drug partition between plasma and whole blood
  • Solubility study
  • Dissociation constant determination (Kd
  • Tissue-binding study using tissue homogenate
Additional Information:
Determining the extent to which a molecule binds to plasma proteins is a critical phase of pharmaceutical development because it influences compound dosing, drug efficacy, clearance rate and potential for drug interactions. This determination is enabled by equilibrium dialysis, an accepted standard method for reliable estimation of the nonbound drug fraction in plasma. Although it is the preferred method, equilibrium dialysis is generally labor-intensive, time-consuming, cost-prohibitive and difficult to automate. The RED Device for rapid equilibrium dialysis was developed in close association with the pharmaceutical industry to specifically address these issues, accelerating lead optimization and reducing the attrition rate. In addition to plasma protein binding, the device is used for determining drug partition between red blood cell and plasma, protein binding of liver microsomes to improve the correlation between in vitro and in vivo intrinsic clearance, the competition between tissue protein binding against plasma proteins and dissociation constant determination (Kd).
The RED Device has been extensively validated for plasma-binding assays producing results consistent with those reported in the literature. For example, when used to measure warfarin binding to plasma (human and rat) proteins at two concentrations of 1µM and 10µM, the RED Device produced results with minimal intra-experimental variability. The offers significant improvements in automation, time requirements, versatility and product reliability compared to other commercially available systems.

The RED Device is compatible with liquid handling systems and can accelerate preclinical AMDE Tox, DMPK, phamacokinetics and bioavailability assays.
Use the RED Device for increased productivity. Each RED Device Base Plate sits in a 96-well plate footprint withe 9 x 9 mm well spacing making it compatible with automated liquid handling systems. Single-Use RED Base Plates are available with inserts preloaded mimimizing setup time.

Rapid Equilibrium Dialysis Device Frequently Asked Questions.

Please click here to see the Rapid Equilibrium Device Demonstration Video.

 

The RED Device reproduces results found in the literature. Performance of pre-loaded Single-Use RED Device Base Plates (Product # 90006) using high, medium and low protein-binding compounds tested at 1 mM on human plasma.
   Human plasma (% bound)
Compound
RED plate
*Other Device
Warfarin
99.24
99
Taxol
96.16
95 to 98
Propanolol
91.81
80 to 92
Vinblastine
99.30
99
Verapamil
90.31
88 to 92
Atenolol
3.50
< 5
Antipyrine
0
0
*Values reported in the literature.2-6

 

The RED Device for comparison of plasma and microsome samples. Comparison of protein bindings between human plasma and human microsome at 1 mM concentration as determined using the Single-Use RED Device.
Compound
Human Plasma, % free
Human Microsome, % free
Warfarin
< 1
81
Taxol
4
20
Propanolol
8
44
Vinblastine
0.7
4
Verapamil
10
27
Methotrexate
50
70
Simvastatin
7
23
Atenolol
97
100
Antipyrine
100
100
*Microsomal protein concentration of 1.0 mg/ml is used in the study

 

The RED Device had many advantages to other methods. The RED Device System offers significant improvements in the ease of use, time requirements, versatility and product reliability compared to other methods.
Device Time to reach Equilibrium Disposable Labor Intensity Automation Accessible Vol. Shift
RED (Rapid Equilibrium Dialysis), (Pierce) 4 Hr Yes + Yes None
96 - well Micro Equilibrium Dialysis block (HTDDialysis, LLC) 6 Hr No +++ Possible Yes
24-Multiwell Dialysis (BD Biosciences) 24 Hr Yes ++ Possible Not measured
Shelley Li1, Bob Xiong2, Tainang Huang2, Lily Li2, John Donovan3, Frank Lee*1, Shaoxia Yu1, Gerald Miwa1, Hua Yang*1
1DMPK/Drug Safety & Disposition, and 3Process Technology, Millennium Pharmaceuticals, Inc. 40 Landsdowne Street, Cambridge, MA 02139 USA and 2Linden Bioscience, 35A Cabot Road, Woburn, MA 01801, USA

Equilibrium can be reached in as little as 100 minutes with mild agitation or 3-4 hours with no agitation.

 

Posters: Download a PDF version of the following posters.

A Practical Method for Measuring Free Drug Concentration in Whole Blood Using an Equilibrium Dialysis Method (Opens new broswer window)
Susan Chen, Ji Zhang, Tai-Nang Huang1, Jing-Tao Wu, Frank W. Lee, and Mark G. Qian DMPK,
1 DMPK/Drug Safety & Disposition, and Process Technology, Millennium Pharmaceuticals, Inc. 40 Landsdowne Street, Cambridge, MA 02139 USA
2 Linden Bioscience, 35A Cabot Road, Woburn, MA 01801, USA
High Throughput Plasma Protein Binding Assay Using – Faster PPB Assay Results Using a 2 Hour Protocol (Opens new broswer window)
Mark G. Qian, Tai-Nang Huang1, Susan Chen, Ji Zhang, Cindy Xia, Chuang Lu, Jing-Tao Wu, and Frank W. Lee
Millennium Pharmaceuticals, Inc. 40 Landsdowne Street, Cambridge, MA 02139 USA
2 Linden Bioscience, 35A Cabot Road, Woburn, MA 01801, USA
Assessment of the Rapid Equilibrium Dialysis (RED) device for the determination of plasma protein binding (PPB). (Opens new broswer window)
Steve Harris, Jonathan Duckworth, Katie Critchell, Charlie Malloy, Christine Tyman and Mark Savage. Pfizer Pharmacokinetics, Dynamics and Metabolism Department, PGRD, Sandwich, Kent , UK
High Throughput Protein Binding Using Rapid Equilibrium Dialysis (Opens new broswer window)
by Kevin L. Cook, Dennis M. Kalamaridis, Jose Silva, Jie Chen, Carlo Sensenhauser, Vangala Subrahmanyam, and H. K. Lim DMPK, GPCD, Johnson & Johnson PRD, Raritan, NJ
Development & Validation of Rapid Equilibrium Dialysis for the Measurement of Plasma Protein Binding (Opens new broswer window)
Rachel Jones, Bindi Sohal, Nigel Waters, Gareth Williams
Metabolism & Pharmacokinetics, Novartis Institutes for Biomedical Research, Horsham, UK
References:
  1. Waters, N.J., et al. (2008). Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding. J Pharm Sci 97(10): 4586-95.
  2. Brouwer, E.J., et al. (2000). Measurement of fraction unbound paclitaxel in human plasma. Drug Metab Disposition 28(10): 1141-5.
  3. Brunton, L., et al. Goodman and Gilman's Pharmacological Basis of Therapeutics. McGraw Hill Publishing: New York, 2005.
  4. Clausen, J. and Bickel, M. (1993). Prediction of drug distribution in distribution dialysis and in vivo from binding to tissue and blood. J Pharm Sci 82: 345-9.
  5. Sonnichsen, D. and Relling, M. (1994). Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 27: 256-69.
  6. Steele, W., et al. (1983). The protein binding of vinblastrine in the serum of normal subjects and patients with Hodgkin's disease. Eur J Clin Pharmacol 24: 683-7.
Related Products and Resources:
New Competition Rapid Equilibrium Dialysis (RED) Products and Accessories
Pierce Protein Precipitation Plates
Sealing Tape for Microplates
Phosphate Buffered Saline
LC/MS Grade Acetonitrile
Trifluoroacetic Acid

Ordering Information
 
 
Product # Description Pkg. Size Instructions MSDS CofA Price
90006 RED Device Single-Use Plate with Inserts, 8K MWCO
Formulation: High-density polypropylene plate with RED Device Inserts
Sufficient For: 1 × 48 experiments
 
1-plate set Product Instructions for product #90006 RED Device Single-Use Plate with Inserts, 8K MWCO Certificate of Analysis for product #90006 RED Device Single-Use Plate with Inserts, 8K MWCO

Local contact
90006B RED Device Single-Use Plate with lnserts, 8K MWCO
Formulation: High-density polypropylene plate with RED Device Inserts
Custom

90007 RED Device Single-Use Plate with Inserts, 8K MWCO
Formulation: High-density polypropylene plate with RED Device Inserts
Sufficient For: 5 × 48 experiments
 
5-plate set Certificate of Analysis for product #90007 RED Device Single-Use Plate with Inserts, 8K MWCO

Local contact
99006 RED Device Single-Use Plate with Inserts, 8K MWCO
Formulation: High-density polypropylene plate with RED Device Inserts
Sufficient For: 10 × 48 experiments
 
10-plate set Certificate of Analysis for product #99006 RED Device Single-Use Plate with Inserts, 8K MWCO

Local contact
89812 RED Device Insert Removal Tool
Formulation: Stainless steel
Sufficient For: Removing columns of RED Inserts from RED Base Plates (reusable)
 
1 tool Certificate of Analysis for product #89812 RED Device Insert Removal Tool

Local contact
89809 RED Device Inserts, 8K MWCO
Formulation: Plastic framed cellulose membrane tube
Sufficient For: 50 equilibrium dialysis experiments with a RED Base Plate (sold separay)
 
50 inserts Product Instructions for product #89809 RED Device Inserts, 8K MWCO Certificate of Analysis for product #89809 RED Device Inserts, 8K MWCO

Local contact
89810 RED Device Inserts, 8K MWCO
Formulation: Plastic framed cellulose membrane tube
Sufficient For: 250 equilibrium dialysis experiments with a RED Base Plate (sold separay)
 
250 inserts Product Instructions for product #89810 RED Device Inserts, 8K MWCO Certificate of Analysis for product #89810 RED Device Inserts, 8K MWCO

Local contact
89811 RED Device Reusable Base Plate
Formulation: High-grade PTFE
Sufficient For: Unlimited (reusable) 48-well experiments with RED Inserts (sold separay)
 
1 plate Certificate of Analysis for product #89811 RED Device Reusable Base Plate

Local contact
90004 RED Device Single-Use Base Plates
Formulation: High-density polypropylene
Sufficient For: 2 × 48 experiments (empty plates; require RED Inserts; sold separay)
 
2 plates Certificate of Analysis for product #90004 RED Device Single-Use Base Plates

Local contact
90005 RED Device Single-Use Base Plates
Formulation: High-density polypropylene
Sufficient For: 10 × 48 experiments (empty plates; require RED Inserts; sold separay)
 
10 plates Certificate of Analysis for product #90005 RED Device Single-Use Base Plates

Local contact



化工儀器網(wǎng)

采購商登錄
記住賬號    找回密碼
沒有賬號?免費注冊

提示

×

*您想獲取產(chǎn)品的資料:

以上可多選,勾選其他,可自行輸入要求

個人信息:

溫馨提示

該企業(yè)已關(guān)閉在線交流功能